PATENT CLAIM ANALYSIS

Application Number: 15987449
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "215000"]

Abstract:
The present invention relates to 5-HT 6  receptor antagonists for the treatment of Alzheimer's disease where the Alzheimer's disease patient carries one or two ApoE4 alleles comprising administering an effective dose of a 5-HT 6  receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.

Claim (Index 25):
The method of  claim 19 , wherein the subject is administered a dose of the pharmaceutically acceptable salt of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine from 30 mg/day to 60 mg/day.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.35135
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15194947', '15696880', '15084712', '14021033', '15323426']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8202230391263936
- 35 USC 102 Novelty (BERT): 0.541778328200025
- Combined Prediction Score: 0.7923785680337568
- Mean Citation Score: 380.656292
- Max Citation Score: 392.42154
- Similarity Product: 300.52436768241404

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test